ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Physalis minima L.: A comprehensive review on phytochemistry, pharmacology, and food applications.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Physalis minima Linn. (Solanaceae) is a widely recognized plant renowned for its diverse medicinal properties and edible applications. Traditionally, this plant has been used to prevent cancer, inflammation, diabetes, Alzheimer's, microbial growth, and leishmaniasis. It is also utilized as a diuretic and laxative. The species has been identified as having various phytoconstituents, including withanolides, flavonoids, fatty acids, and other compounds. Among these, withanolides are the most prevalent and function as the primary bioactive compounds. A total of 221 withanolides (1980-2025) were documented in this review, among which 81 were newly identified from P. minima. Previous research has identified withanolides as key bioactive constituents with notable potential in the management of inflammatory, neuroinflammatory, and cancer-related conditions, largely due to their distinctive steroidal framework and significant biological activities. Despite these promising pharmacological attributes, only a limited number of withanolides have been studied in depth. Most compounds, especially those discovered more recently, remain insufficiently explored with respect to their therapeutic potential. This knowledge gap highlights the need to further investigate compounds isolated from P. minima to better understand their pharmacological effects. We have tried to extensively appraise the data on phytoconstituents identified from this plant and their associated pharmacological activities. Collectively, the findings presented in this review provide a starting point for future research on P. minima, highlighting its promise as a valuable source of bioactive compounds for drug discovery.
Indexed as
Identifiers
42151567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.